Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/10/059253
CTRI/2023/10/059253
Not yet recruiting
Phase 4

Clinical efficacy and safety of Fluticasone furoate with cetrizine vs Fluticasone furoate with montelukast in patients with allergic rhinitis - A Randomized open label controlled trial

SRM institute of science and technology0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: J309- Allergic rhinitis, unspecified

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: J309- Allergic rhinitis, unspecified
Sponsor
SRM institute of science and technology
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Willing to sign informed consent form.
  • •Patients suffering from Allergic Rhinitis.
  • •Not being using Nasal steroids for past one month.
  • •4 out of 12 Total Nasal Symptom Score(TNSS).

Exclusion Criteria

  • •Pregnancy and lactating women.
  • •Known history of psychiatric illness.
  • •Planned surgery of nasal cavity.
  • •Patient with unknown malignancies.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPD
EUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-SEGlaxoSmithKline Research & Development Limited3,000
Completed
Phase 4
The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY ELLIPTA) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients within a Usual Care Setting.(study 206854)
NL-OMON48721GlaxoSmithKline700